Ablation of Goalpha Overrides G1 Restriction Point Control through Ras/ERK/Cyclin D1-CDK Activities*

(Received for publication, February 4, 1997, and in revised form, April 30, 1997)

Jason D. Weber Dagger , Jie Cheng §, Daniel M. Raben §, Alice Gardner and Joseph J. Baldassare Dagger par

From the Dagger  Department of Cell and Molecular Biology and the  Department of Pharmacological and Physiological Sciences, St. Louis University School of Medicine, St. Louis, Missouri 63104 and the § Department of Physiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

We have generated stable IIC9 cell lines, Goa1 and Goa2, that overexpress full-length antisense Goalpha RNA. As shown previously, expression of antisense Goalpha RNA ablated the alpha  subunit of the heterotrimeric G protein, Go, resulting in growth in the absence of mitogen. To better understand this change in IIC9 phenotype, we have characterized the signaling pathway and cell cycle events previously shown to be important in control of IIC9 G1/S phase progression. In this paper we clearly demonstrate that ablation of Goalpha results in growth, constitutively active Ras/ERK, elevated expression of cyclin D1, and constitutively active cyclin D1-CDK complexes, all in the absence of mitogen. Furthermore, these characteristics were abolished by the transient overexpression of the transducin heterotrimeric G protein alpha  subunit strongly suggesting the transformation of Goalpha -ablated cells involves Gobeta gamma subunits. This is the first study to implicate a heterotrimeric G protein in tumor suppression.


INTRODUCTION

In IIC9 cells, a subclone of Chinese hamster embryo fibroblasts, platelet-derived growth factor (PDGF)1 is a potent mitogen (1). PDGF stimulates an increase in cyclin D1 expression concomitant with an increase in cyclin D1-CDK activity (1). Cyclin D1 is an important G1 protein in that its delayed early induction in response to mitogen is required for G1 progression (2). Microinjection of cyclin D1 antibodies or antisense cyclin D1 plasmids into normal fibroblasts arrests them in G1 but has no effect on cells already beyond the G1/S boundary (3, 4). Thus, accumulation of cyclin D1 in G1 in response to mitogen is required for progression through the restriction point and entrance into S phase (2, 5, 6). Cyclin D1 preferentially binds to its catalytic partner, cyclin-dependent kinase 4 (CDK4), to form a holoenzyme (7-10). The activated cyclin D1-CDK4 complex preferentially binds to and phosphorylates the retinoblastoma gene product (pRb) (11-16). Hence, the mitogen-induced activation of cyclin D1-CDK4 complexes allows for progression through the restriction point in vivo presumably through the hyperphorylation and inactivation of pRb in concert with other G1 cyclin-CDK complexes.

We and others previously have shown that PDGF stimulates ERK1 activity in IIC9 and CCL39 cells and that inhibition of this activity is sufficient to cause the loss of PDGF-induced cyclin D1 expression, as well as a loss of cyclin D1-CDK activity (1). The loss of PDGF-induced cyclin D1-CDK activity was correlated with G1 growth arrest. Attention has focused on the mitogen-induced signals involved in cell growth and more recently those signals regulating mitogen-dependent induction cyclin D1 (1, 6). Expression of constitutively active mutant Ras has been shown to transform several cell types and elevate cyclin D1 expression (3, 17-19). The role of Ras proteins in the mitogenesis and transformation of cells is mediated, in part, by a downstream cascade of serine-threonine kinases that terminates with the activation of p42 and p44 MAPKs (ERK1, ERK2). Activated ERKs phosphorylate several nuclear factors that control gene expression. Evidence for the role of the Ras-mediated MAPK cascade is well documented with kinase-deficient mutants of Raf-1, MEK and MAPKs inhibiting Ras transformation.

Recent evidence has shown that Goalpha activates ERK (20). Goalpha activation of ERK is mediated by a novel protein kinase C-dependent mitogenic signaling pathway which is independent of Ras activation. The studies reported here examine the effects of ablation of Goalpha by overexpression of antisense Goalpha RNA in IIC9 cells on the Ras/ERK pathway and cell cycle activities known to be important in mitogen-induced growth. Currently, there is evidence suggesting that beta gamma subunits from pertussis toxin-sensitive heterotrimeric G proteins are capable of ERK activation through a Ras-dependent signaling pathway (20-23). The beta gamma -mediated ERK activation is blocked by the expression of dominant negative Ras (22). Our data demonstrate that loss of Goalpha expression in IIC9 cells results in unregulated growth by constitutively activating the Ras/ERK pathway, a pathway we and others have shown positively regulates cyclin D1-CDK activity through the increased expression of cyclin D1.


EXPERIMENTAL PROCEDURES

Cells and Cell Culture

IIC9 cells, a subclone of Chinese hamster embryo fibroblasts (46), were grown and maintained in DMEM (Life Technologies, Inc., Grand Island, NY) containing 10% fetal calf serum and 2 mM L-glutamine (all chemicals were obtained from Sigma, unless specified otherwise). Subconfluent cultures were growth-arrested by washing once with serum-free DMEM and cultured for 48-60 h in serum-free media. PDGF was obtained from Calbiochem (La Jolla, CA). Stable Goalpha antisense transfectants were produced and maintained as described previously (48). Briefly, pcDNAI containing Goalpha cDNA in an antisense orientation to the cytomegalovirus promoter was transfected into IIC9 cells using LipofectAmineTM protocol (Life Technologies, Inc.). Following an 18-h transfection period, cells were cultured for 48 h in DMEM containing 10% fetal calf serum to allow for the expression of neomycin-resistant gene products. Transfected IIC9 cells were grown for several weeks in selection media containing G418 (500 µg/ml). G418-resistant clones were isolated and subcultured in DMEM containing 10% fetal calf serum and 250 µg/ml G418. Several Goalpha -ablated clones were isolated of which two, Goa1 and Goa2 (described in the previous paper (48)), were used for the studies in this paper. The experiments in this paper utilized both clones even though the data presented is only that of the Goa1 clone.

Transient transfection of IIC9 cells using LipofectAmineTM resulted in 85-90% expression efficiency as visualized by beta -galactosidase staining. IIC9 cells were also transiently transfected with Goalpha antisense cDNA (3 µg/ml) for 18 h. Transfected cells were stimulated with serum for 20-24 h and cultured in serum-free media for 48 h for subsequent experiments. Similarly, Goa1 cells were transiently transfected with Gtalpha cDNA (3 µg/ml) to achieve the phenotype of the Goa1/Gtalpha cell type. However, Goa1/Gtalpha cells were cultured in serum-free media for only 24 h to ensure the continued expression of Gtalpha protein in the absence of mitogen.

Western Blots

PDGF (10 ng/ml) was added directly to serum-deprived IIC9 and Goa1 cells. Cells (1-2 × 106) were then harvested at 24 h after addition of PDGF by scraping in cold 1 × PBS. Harvested cells were pelleted at 10,000 × g for 5 min and lysed with 30 µl of solubilization buffer (25 mM Hepes, 300 mM NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 0.1% Triton X-100, 20 mM beta -glycerophosphate, 0.1 mM sodium vanadate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 0.5 mM phenylmethylsulfonyl fluoride).

IIC9 and Goa1 cells were incubated with aphidicolin (5 µg/ml) for 12-16 h to achieve growth arrest. Arrested cells were released by washing twice with DMEM and incubating in serum-free DMEM. Cells were then harvested and lysed 8 h after release from aphidicolin arrest as described above. Protein concentrations of lysates were determined by Bio-Rad Protein Assay (Bio-Rad) as recommended by the manufacturer. Lysates/proteins (15 µg) were electrophoresed on 10% SDS-polyacrylamide gels. Separated proteins were then transferred to polyvinylidene difluoride membranes (Millipore, Boston, MA). Membranes were probed with a cyclin D1 polyclonal antibody (Santa Cruz Biotechnology). Goat anti-rabbit IgG (H+L) horseradish peroxidase conjugate (Bio-Rad) was added as the secondary antibody and specific protein bands were visualized using ECL (Amersham) as recommended by the manufacturer.

Northern Blots

Total RNA was isolated from IIC9 and Goa1 cells (4-8 × 106) cultured on 100-mm dishes with Trizol Reagent (Life Technologies, Inc.) using the manufacturer's protocol. RNA was electrophoresed on 2% agarose/formaldehyde gels. Formaldehyde was removed by washing gels in 0.5 M ammonium acetate. RNA was transferred onto Hybond N+ nylon membranes (Amersham) using the TurboblotterTM system (Schleicher & Schuell, Keene, NH). RNA was cross-linked onto membranes with an Ultraviolet Crosslinker (Amersham) using the manufacturers protocol. Transferred RNA was visualized using a methylene blue/sodium acetate stain. Randomly-labeled [alpha -32P]dCTP cDNA probes (murine cDNA for cyclin D1 was a generous gift from Dr. Charles Sherr) were made using the Random Primed DNA Labeling Kit (Boehringer Mannheim, Germany). Blots were probed simultaneously with cyclin D1 and glyceraldehyde-3-phosphate dehydrogenase probes for 2 h at 65 °C using Rapid-hyb buffer (Amersham) and washed once at room temperature with 5 × SSPE (20 mM EDTA, 1 M NaCl, 50 mM NaH2PO4-H2O), 0.1% SDS and subjected to either autoradiography or direct quantitation with a PhosphorImagerTM (Molecular Dynamics). More stringent washes were done at 65 °C with 0.5% SDS when necessary.

Thymidine Incorporation

Thymidine incorporation was performed as described previously (1) with minor modifications. Briefly, growth-arrested IIC9 cells were stimulated with PDGF (10 ng/ml) for approximately 20 h. Goa1 cells were serum-starved by washing twice with DMEM and incubated for 48 h in serum-free DMEM supplemented with 2 mM L-glutamine. To growth-arrest Goa1 cells, aphidicolin (5 µg/ml) was added to serum-deprived cells as described above. Following a 24-h incubation, aphidicolin-arrested cells were released from arrest by washing twice with DMEM. Following primary incubation, cells were incubated for 3 h with 1 µCi of [3H]thymidine/ml (NEN Life Sciences Products). 3H-Labeled cells were washed twice with cold 1 × PBS and the DNA was precipitated by incubating the cells for 30 min with cold 5% trichloroacetic acid. The trichloroacetic acid-precipitated DNA was washed twice with cold 5% trichloroacetic acid and solubilized with 2% sodium bicarbonate, 0.1 N NaOH. The solution was neutralized by addition of one-fifth volume of 5% trichloroacetic acid and the trichloroacetic acid-precipitated [3H]DNA was quantitated by scintillation counting.

ERK Assay

Growth-arrested IIC9 cells were stimulated with mitogen at 37 °C. After 15 min the media was removed and the cells were washed with 1 × PBS. Goa1 cells were either grown in serum (10%), serum-starved for 48 h, arrested with aphidicolin (5 µg/ml), or released from aphidicolin arrest for 8 h as described above and washed with 1 × PBS. After washing, cells were lysed by scraping in 300 µl of solubilization buffer (20 mM Tris-HCl, pH 8, 1 mM sodium vanadate, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 2 mM EDTA, 1% Triton X-100, 50 mM beta -glycerophosphate, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 10 µg/ml pepstatin). The lysates were assayed for ERK activity as described previously (1).

Cyclin D1/CDK Kinase Assay

Cyclin D1/CDK activity was assayed as described previously (8) with modifications. Briefly, growth-arrested IIC9 cells were stimulated with PDGF (10 ng/ml) and harvested at 0 and 24 h after stimulation by scraping in cold 1 × PBS and lysed in 50 µl of IP buffer (50 mM Hepes, 150 mM NaCl, 0.1 mM sodium vanadate, 1 mM EDTA, 2.5 mM EGTA, 1 mM dithiothreitol, 10 mM beta -glycerophosphate, 1 mM sodium fluoride, 0.1% Tween 20, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 10 µg/ml pepstatin). Goa1 cells were grown in serum, serum-deprived for 48 h, aphidicolin-arrested, or released from aphidicolin arrest for 8 h and harvested by scraping in cold 1 × PBS. Lysates were sonicated briefly and insoluble material was pelleted by centrifugation at 10,000 × g for 10 min. Cyclin D1 monoclonal antibody (2 µg) was added to supernatants and incubated at 4 °C. After 1-2 h cyclin D1 complexes were precipitated for 2-3 h with protein G-Sepharose. Cyclin D1 immune complexes were washed 4 times with 1 ml of cold IP buffer and 2 times with 1 ml of cold wash buffer (50 mM Hepes, 10 mM MgCl2, and 1 mM dithiothreitol). Cyclin D1 immune complexes were pelleted and resuspended in 30 µl of reaction buffer (50 mM Hepes, 10 mM MgCl2, 1 mM dithiothreitol, 2.5 mM EGTA, 10 mM beta -glycerophosphate, 0.1 mM sodium vanadate, and 20 µM ATP). The immune complexes were incubated for 30 min at 30 °C with 2 µg/ml soluble GST-Rb fusion protein (GST-Rb cDNA was a generous gift from Dr. Mark Ewen) and 5 µCi of [gamma -32P]ATP. The reaction was stopped by addition of 15 µl of 2 × Laemmli sample buffer. Samples were boiled for 5 min and subjected to SDS-polyacrylamide electrophoresis. Gels were dried and subjected to autoradiography.

Analysis of GDP and GTP-bound Ras

The assay is a modification of the protocol by Downward et al. (47). Serum-deprived IIC9 cells or Goa1 cells were labeled for 18 h with [32P]Pi at 0.2 mCi/100 mM dish in phosphate-free DMEM. Cells were washed twice with phosphate-free media and with a saline buffer (50 mM Tris-HCl, pH 7.5, and 150 mM NaCl). Cells were incubated with PDGF (10 ng/ml) for 15 min and washed twice with cold 1 × PBS. Cells were harvested and lysed by scraping in 500 µl of IP buffer (50 mM Tris-HCl, pH 7.5, 20 mM MgCl2, 150 mM NaCl, 1% Triton X-100, 2 mM p-nitrophenyl phosphate, 10 µg/ml pepstatin, 10 µg/ml aprotinin, and 10 µg/ml leupeptin). After a 10-min incubation the homogenate was centrifuged at 750 × g for 5 min. The supernatant was treated with 100 µl of bovine serum albumin-coated charcoal for 5 min at 4 °C and then centrifuged at 750 × g to remove charcoal. A monoclonal p21ras antibody (Oncogene) was added to supernatants and Ras immune complexes were precipitated with protein G plus agarose (Oncogene) overnight at 4 °C. The precipitate was washed twice with IP buffer and 3 times with wash buffer (Tris-HCl, pH 7.5, 20 mM MgCl2, and 150 mM NaCl). Final pellets were drained and bound nucleotides were eluted in 20 µl of elution buffer (20 mM Tris-HCl, pH 7.5, 20 mM EDTA, 2% SDS, 0.5 mM GDP, and 0.5 mM GTP). Eluants were heated at 65 °C for 5 min and centrifuged. The supernatant was spotted onto a polyethyleneimine-cellulose thin layer plate (Merck) and developed with 0.75 M KH2PO4 (pH 3.4). GDP and GTP 32P-labeled fractions were quantified by scintillation counting.


RESULTS AND DISCUSSION

Goa1 Cells Do Not Exit the Cell Cycle upon Removal of Mitogen

We previously generated a panel of stable IIC9 clones (including Goa1 and Goa2 clones) overexpressing full-length Goalpha RNA (48). We examined the phenotype of two of these clones, Goa1 and Goa2. In contrast to IIC9 cells, Goa1 and Goa2 cells do not express Goalpha protein. Goa1 and Goa2 cells formed multiple foci in monolayer cultures and anchorage independent colonies in soft agar (48).

To understand the mechanism for the transformed phenotype of these cells, we examined whether Goa1 cells growth arrested upon removal of mitogen. Goa1 cells did not growth arrest upon removal of serum (Fig. 1A) and flow cytometry showed Goa1 cells randomly distributed throughout the cell cycle with a slight majority of cells in S phase (data not shown). To arrest and synchronize populations of mitogen-independent Goa1 cells, aphidicolin, a novel DNA polymerase alpha  inhibitor, was utilized. Addition of aphidicolin in the absence of serum resulted in growth arrest within 12-16 h after treatment (Fig. 1B). Previous studies have shown that removal of aphidicolin by washing with serum-free media is sufficient to allow cells to enter S phase in the absence of mitogen within 4-8 h (5). However, aphidicolin-released cells arrest when they reach the subsequent G1/S restriction point of the next cycle. Goa1 cells resumed cell cycle progression after release from aphidicolin in serum-free media and continued through subsequent cycles in the absence of mitogen while IIC9 cells arrested at the proceeding G1/S restriction point (Fig. 1B) further demonstrating the mitogen-independent growth of Goa1 cells. Transient overexpression of Goalpha antisense RNA also resulted in mitogen-independent growth suggesting that the transformed phenotype of the stable Goa1 cell type is a result of Goalpha ablation and not a result of a deletion of another gene due to homologous recombinantion (data not shown).


Fig. 1. Mitogen-independent growth of Goa1 cells. IIC9 and Goa1 cells were grown and serum-deprived for 48 h as described under "Experimental Procedures" in 6-well (35-mm2) dishes. A, after serum deprivation IIC9 and Goa1 cells were incubated in the absence (open bars) or presence (solid bars) of PDGF (10 ng/ml) for 20 h and then assayed for [3H]thymidine incorporation as described under "Experimental Procedures." B, alternatively serum-deprived IIC9 and Goa1 cells (open bars) were supplemented with aphidicolin (5 µg/ml) for 12 h and assayed for [3H]thymidine incorporation, or aphidicolin (solid bars) was removed by washing with fresh serum-free media and cells incubated in serum-free media for 24 h and [3H]thymidine incorporation determined. The data indicate the mean ± S.D. (n = 3).
[View Larger Version of this Image (12K GIF file)]

Ablation of Goalpha Results in the Mitogen-independent Activation of Ras

IIC9 cells overexpressing constitutively activated Ras form multiple foci when grown in soft agar and do not growth arrest when serum-depleted (data not shown). To examine whether the Ras pathway was involved in the transformation of Goa1 cells we first examined Ras activation. In growth-arrested IIC9 cells, levels of activated Ras as determined by the ratio GTP/(GTP + GDP) associated with Ras were quite low (Fig. 2) and increased 6-fold within 5 min after the addition of PDGF (Fig. 2) or several other growth factors (data not shown). In contrast, Goa1 cells exhibited high levels of activated Ras in the absence of mitogen similar to levels found in IIC9 cells treated with PDGF (Fig. 2). Addition of PDGF did not increase the level of activated Ras above the levels seen in serum-depleted Goa1 cells. Similar results were observed with a second clonal Goalpha -ablated cell line (Goa2) (data not shown) indicating that ablation of Goalpha in IIC9 cells results in significant activation of Ras. These results are consistent with the observed inability of these cells to growth arrest with the removal of mitogen and suggest that in certain cell types loss of Goalpha could result in neoplastic transformation.


Fig. 2. Ras activation is elevated in unstimulated Goa1 cells. IIC9 and Goa1 cells were grown and serum-deprived for 48 h as described under "Experimental Procedures" in 6-well (35-mm2) dishes. After serum deprivation, IIC9 and Goa1 cells were incubated in the absence (open bars) or presence (solid bars) of PDGF (10 ng/ml) for 15 min and assayed for 32P-labeled GDP and GTP associated with Ras immunoprecipitations by thin layer chromatography as described under "Experimental Procedures." Ras activity is reported as the ratio of GTP/(GTP + GDP) quantified by scintillation counting of labeled fractions. Results are reported as the means ± S.D. (n = 3).
[View Larger Version of this Image (18K GIF file)]

Goa1 Cells Exhibit Constitutively Active ERK

Recent data from several laboratories has suggested the importance of ERK activation in Ras-dependent growth. We have previously demonstrated that suppression of PDGF-induced ERK activation blocked G1 progression in IIC9 cells (1). To determine whether ablation of Goalpha resulted in constitutive activation of the ERK pathway, we next examined the endogenous activity of ERK in Goa1 cells. Addition of PDGF (Fig. 3) and several other growth factors (data not shown) to growth-arrested IIC9 cells increased ERK activity approximately 7-8-fold within 15 min. As previously found in CCL39 cells (24) and IIC9 cells (1) addition of thrombin or PDGF to growth-arrested cells induced a biphasic increase in ERK activity. A rapid 8-12-fold increase of ERK activity within 5-10 min is followed by a sustained 4-6-fold increase in ERK activity. Asynchronous Goa1 cells grown in serum-free media express levels of ERK activity (7-9-fold) (Fig. 3) similar to the levels of ERK activity of IIC9 cells stimulated with PDGF (Fig. 3).


Fig. 3. Goa1 cells exhibit constitutively active ERK. IIC9 and Goa1 cells were grown and serum-deprived for 48 h as described previously. IIC9 and Goa1 cells incubated in the absence (open bars) or presence (solid bars) of PDGF (10 ng/ml) for 15 min. Cells were assayed for ERK activity as described under "Experimental Procedures." Results reported are the mean ± S.D. (n = 4).
[View Larger Version of this Image (17K GIF file)]

Elevated Expression of Cyclin D1 in the Absence of Mitogen

An ERK-responsive region has recently been identified in the cyclin D1 promoter (25) and we have previously shown that addition of PDGF to IIC9 cells induces cyclin D1 mRNA and protein expression (1). In addition, we and others have shown that inhibition of mitogen-induced ERK activity blocks expression of cyclin D1 and progression of IIC9 cells through G1 (1, 6). Many tumor cell lines express elevated levels of oncogenic Ras and cyclin D1 (26-28). To identify a possible downstream target of the Goa1 constitutively active Ras/ERK pathway, we measured levels of cyclin D1. Goalpha ablation conferred increased cyclin D1 protein expression by approximately 3-4-fold (Fig. 4A). The levels of cyclin D1 in Goa1 cells remained constitutively elevated in the absence of mitogen.


Fig. 4. Goa1 cells display mitogen-independent expression of cyclin D1. A, IIC9 and Goa1 cells were grown and serum-deprived for 48 h as described previously. IIC9 cells were then incubated for 24 h with no serum (SS) or with 10 ng/ml PDGF. Goa1 cells were incubated with no serum (SS) or 10% serum (Serum) for 24 h. Conversely, serum-deprived IIC9 and Goa1 cells were supplemented with 5 µg/ml aphidicolin (APH) for 12 h. Aphidicolin was removed by washing with fresh media and both IIC9 and Goa1 cells were incubated in serum-free media for an additional 5 h (aphidicolin release; AR). IIC9 and Goa1 cells were lysed as described previously and all lysates were immunoblotted with a polyclonal mouse cyclin D1 antibody as described under "Experimental Procedures." B, serum-deprived IIC9 cells were incubated in the absence (SS) or presence of 10 ng/ml PDGF (PDGF) for 24 h. Serum-deprived Goa1 cells were unsupplemented (SS) or supplemented with 5 µg/ml aphidicolin for 12 h or aphidicolin was removed by washing with fresh media and cells incubated in serum-free media for an additional 5 h (AR). IIC9 and Goa1 cells were lysed and RNA extracted using TrizolTM as described under "Experimental Procedures." RNA was electrophoresed on 2% agarose/formaldehyde gels and transferred onto Hybond N+ membranes. Membranes were probed simultaneously with [32P]CTP-labeled murine cyclin D1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA as described under "Experimental Procedures." C, serum-deprived IIC9 cells were incubated in the absence (SS) or presence of 10 ng/ml PDGF (PDGF) for 24 h. Serum-deprived Goa1 cells were unsupplemented (SS) or supplemented with 5 µg/ml aphidicolin (APH) for 12 h or aphidicolin was removed by washing with fresh media and cells incubated in serum-free media for an additional 5 h (AR). IIC9 and Goa1 cells were lysed and lysates incubated with a cyclin D1 monoclonal Ab for 1-2 h at 4 °C. Cyclin D1 immune complexes were precipitated with protein G-Sepharose and immunoprecipitated complexes assayed for their ability to phosphorylate soluble GST-Rb fusion protein in vitro as described under "Experimental Procedures."
[View Larger Version of this Image (22K GIF file)]

We next investigated the effect of aphidicolin arrest and release on cyclin D1 expression. Treatment of Goa1 cells with aphidicolin for 12 h resulted in sustained levels of cyclin D1 protein in the absence of mitogen (Fig. 4A). Matsushime et al. (5) previously showed that Bac1.2F5A macrophages released from aphidicolin arrest required the presence of growth factor (CSF-1) to sustain the expression of cyclin D1. Release of IIC9 cells from aphidicolin arrest in the absence of PDGF resulted in the rapid (within 5 h) decrease in the levels of cyclin D1 protein (Fig. 4A). However, cyclin D1 protein levels in Goa1 cells did not decrease significantly when released from aphidicolin in the absence of PDGF suggesting a significant difference in the requirement of sustained presence of growth factor for cyclin D1 expression. It is clear that the constitutive activation of the Ras/ERK pathway (Figs. 2 and 3) provides the sustained mitogenic signals required for the continued expression of cyclin D1. Cyclin D1 protein expression remained high through the next round of replication (approximately 24 h after aphidicolin release) (Fig. 4A). In the absence of mitogen, cyclin D1 mRNA levels in Goa1 cells were similar to the levels found in IIC9 cells treated with PDGF (Fig. 4B). Aphidicolin-treated and released Goa1 cells exhibited a 1.6-fold decrease in cyclin D1 mRNA expression although these levels were still 3-fold higher than serum-deprived IIC9 cells (Fig. 4B) providing further evidence for the positive role of the Ras/ERK pathway in sustaining cyclin D1 expression in Goa1 cells in the absence of mitogen.

Cyclin D1-CDK Complexes Are Constitutively Active

Phosphorylation of Rb by active cyclin D1-CDK complexes has been demonstrated to be required for progression through G1 in several cell types (12-16). Although several transformed tumor cells express abnormally high levels of cyclin D1, the role of cyclin D1 in tumor formation is unclear. However, cyclin D1-CDK activity is thought to play an important role in mitogen-induced progression of cells through G1. In the absence of mitogen, IIC9 cells contain low levels of cyclin D1-CDK activity (Fig. 4C). PDGF treatment induced a 6-fold increase in cyclin D1-CDK activity within 4 h (data not shown) and sustained this level of activity through 24 h (Fig. 4C). In contrast to IIC9 cells, Goa1 cells display significant cyclin D1-CDK activity in the absence of mitogen (Fig. 4C). In addition, treatment of Goa1 cells with PDGF did not increase further cyclin D1-CDK activity (data not shown). Treatment of Goa1 cells with aphidicolin as well as release from aphidicolin arrest in serum-free media did not result in a decrease in cyclin D1-CDK activity (Fig. 4C) further correlating the mitogen independence of Goa1 cells with the activation of the cyclin D1-CDK complexes in the absence of mitogen. Preliminary results from our laboratory also suggest that high levels of cyclin D1-CDK activity are required to retain the transformed phenotype of Goa1 cells. These data further suggest that in certain cell types Ras transformation involves the up-regulation of cyclin D1-CDK activity.

A Possible Role for Gobeta gamma Subunits in Goa1 Transformation

The ablation of Goalpha from IIC9 cells provides interesting insights into the mechanisms of G1 progression as well as cellular transformation. Ablation of Goalpha from IIC9 cells results in growth and high levels of Ras activity in the absence of mitogen (Fig. 2). In addition, Goa1 cells contain constitutive levels of ERK activity (Fig. 3) as well as cyclin D1-CDK activity (Fig. 4C). We and others have shown that ERK activity is essential for mitogen-induced expression of cyclin D1 and subsequent cyclin D1-CDK activity. Inhibition of ERK activity not only resulted in a concomitant loss of cyclin D1-CDK activity but also resulted in growth arrest (1). These data show that Ras transformation through the ablation of Goalpha results in sustained cyclin D1-CDK activity and suggest that in certain cell types Ras transformation may involve up-regulation of cyclin D1-CDK activity.

Recent evidence demonstrating that the Goalpha subunit stimulates ERK activity through a Ras-independent mechanism suggested a role for Goalpha in ERK activation (20). Ablation of Goalpha from IIC9 cells resulted in constitutive elevation of Ras and ERK activation in the absence of mitogenic stimulation. Several studies, however, have provided new insights into G protein-coupled signaling (29). Overexpression of beta gamma subunits also activates the Ras/ERK pathway (21, 22). In addition, several studies present findings suggesting that Gbeta gamma activates the Ras/ERK pathway through the recruitment of cytosolic or membrane-associated factors containing pleckstrin homology domains or through direct activation of Gbeta gamma with Ras (29). Transfection of a bARKct Gbeta gamma antagonist which contains a beta gamma -binding region significantly reduces Ras activation (23). Furthermore, transfection of dominant negative Ras eliminates ERK activation suggesting that Gbeta gamma -mediated ERK activation involves Ras (22).

To determine whether the transformation of Goa1 cells was mediated by Gbeta gamma activation of the Ras/ERK pathway in the absence of Goalpha , we transiently transfected Goa1 cells with Gtalpha (Goa1/Gtalpha ) which has previously been used to sequester Gbeta gamma subunits (21, 22). Transient overexpression of Gtalpha did not result in the expression of Goalpha protein, demonstrating continued ablation of Goalpha in the presence of Gtalpha (data not shown). As observed in IIC9 cells, Goa1/Gtalpha cells growth arrested when cultured in the absence of mitogen (Fig. 5A). Stimulation with PDGF resulted in progression through S phase and this progression was inhibited by addition of aphidicolin as described previously (Fig. 1). In contrast to Goa1 cells, stimulation of Goa1/Gtalpha cells with PDGF resulted in a significant increase in [3H]thymidine incorporation as compared with mitogen-deprived cells (Fig. 5A). Goa1/Gtalpha cells also required the presence of PDGF after release from aphidicolin arrest for entrance into S phase 24 h after release (data not shown).


Fig. 5. Overexpression of Gtalpha restores mitogen-dependent phenotype to Goa1 cells. Goa1 cells were serum-deprived for 48 h or transiently transfected with Gtalpha cDNA (3 µg/ml) (Goa1/Gtalpha cells) and grown for 24-48 h in serum supplemented media. Goa1/Gtalpha cells were then serum deprived for 16 h. A, serum-deprived Goa1/Gtalpha and Goa1 cells were incubated in the absence (open bars) or presence (solid bars) of PDGF (10 ng/ml) for 20 h and assayed for [3H]thymidine incorporation as described under "Experimental Procedures." B, serum-deprived Goa1/Gtalpha and Goa1 cells were incubated in the absence (open bars) or presence (solid bars) of PDGF (10 ng/ml) for 15 min and assayed for ERK activity as described under "Experimental Procedures." C, serum-deprived IIC9, Goa1, and Goa1/Gtalpha cells were incubated either in the absence (open bars) or presence (solid bars) of PDGF (10 ng/ml) for 24 h, or serum-deprived IIC9, Goa1, and Goa1/Gtalpha cells were supplemented with aphidicolin (5 µg/ml) for 12 h. Gray bars, in those cells treated with aphidicolin, aphidicolin was removed by washing with fresh media and the cells incubated in serum-free media for an additional 5 h. Cells were lysed and RNA extracted using TrizolTM as described previously. RNA was electrophoresed on 2% agarose/formaldehyde gels and transferred onto Hybond N+ membranes. Membranes were probed simultaneously with [32P]CTP-labeled murine cyclin D1 and glyceraldehyde-3-phosphate dehydrogenase cDNA as described under "Experimental Procedures." Results are reported as the mean ± S.D. (n = 3) of cyclin D1 normalized to glyceraldehyde-3-phosphate dehydrogenase as quantitated by a PhosphorImagerTM. D, serum-deprived IIC9, Goa1, and Goa1/Gtalpha cells were incubated in the absence (SS) or presence of PDGF (10 ng/ml) for 24 h and assayed for cyclin D1-CDK activity as described under "Experimental Procedures." Gels were dried and scanned with a PhosphorImagerTM and viewed using Lview Pro 1.D© Software (MMedia Research Corp.).
[View Larger Version of this Image (27K GIF file)]

Goa1/Gtalpha cells displayed a 60-70% decrease in ERK activity compared with unstimulated Goa1 cells (Fig. 5B). Addition of PDGF to Goa1/Gtalpha cells resulted in a marked stimulation of ERK activity demonstrating that these cells were able to respond to PDGF (Fig. 5B). These data demonstrate that transfection of Gtalpha significantly reduces ERK activity in unstimulated Goa1/Gtalpha cells but does not inhibit the ability of PDGF to stimulate ERK activity in Goa1/Gtalpha cells. Cyclin D1 expression in IIC9 cells as well as macrophages requires mitogen after release from aphidicolin arrest (5). Absence of mitogen results in a rapid decrease in cyclin D1 (Fig. 4A). However, withdrawal of PDGF from Goa1 cells did not decrease cyclin D1 levels (Fig. 4, A and B). This regulation is restored in Goa1/Gtalpha cells. Release of Goa1/Gtalpha cells from aphidicolin arrest results in a 2.5-fold decrease of cyclin D1 mRNA expression (Fig. 5C). Concomittant with a decrease in cyclin D1 protein and mRNA expression, cyclin D1-CDK activity was significantly reduced in Goa1/Gtalpha cells in the absence of PDGF (Fig. 5D). It is important to note that the decrease in cyclin D1-CDK activity is due to cyclin D1 down-regulation since the levels of inhibitors of this complex (p27KIP1 and p16INK4) are relatively high in cycling Goa1 cells.2

These data suggest that sequestration of Gobeta gamma by Gtalpha results in a reversal of the Goa1 phenotype rendering the cells sensitive to the machinery involved in the regulation of cell cycle progression. This results in the restoration of mitogen-induced regulation of cyclin D1 expression and its role in G1 progression. Previous results from our laboratory (1) and others (6) show that mitogen-induced ERK activation is required for growth and the positive regulation of cyclin D1 expression. Preliminary results from our laboratory now suggest that ERK activation absolutely is required to maintain the transformed phenotype of Goa1 cells independent of Gobeta gamma -mediated signaling.2

This is the first study to implicate a heterotrimeric G protein, Goalpha , in tumor suppression. We have shown that ablation of Goalpha from IIC9 cells results in cellular transformation (48) and that this involves the constitutive activation of the Ras/ERK pathway and the mitogen-independent activation of cyclin D1-CDK complexes. Transient ablation of Gq, Gi2, and Gi3 in IIC9 cells did not result in an increase in basal ERK activity in the absence of mitogenic stimulation suggesting that only the specific beta gamma associated with Goalpha activate the Ras/ERK pathway.3 The possibility that Goalpha is a tumor suppressor becomes more intriguing by its genomic location. The Goalpha gene (GNAO1) is located on chromosome 16 at position 16q13 and is the only heterotrimeric G protein gene on chromosome 16 (30-33). The instability of chromosome 16 has been well documented and has led to the discovery of several break points in its lower (q) arm (34-38). These chromosomal abnormalities (translocations and deletions) are now thought to be associated with a wide array of human cancers including breast, prostate, colorectal, pituitary, alveolar, Ewing sarcomas, Wilms' tumors, and turban tumors all of which map near or at the 16q13 region (34, 36-38, 39-45). Our data is the first to implicate Goalpha in tumor suppression and warrants further investigation into the apparent tumor suppressive properties of Goalpha .


FOOTNOTES

*   This work was supported by National Institutes of Health Grants HL40901 (to J. J. B.) and GM51593 (to D. M. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
par    To whom correspondence should be addressed: Dept. of Pharmacological and Physiological Sciences, St. Louis University Medical School, 1402 South Grand Blvd., St. Louis, MO 63104. Tel.: 314-577-8543; Fax: 314-577-8233; E-mail: baldasjj{at}wpogate.slu.edu.
1   The abbreviations used are: PDGF, platelet-derived growth factor; ERK1, extracellular signal-related kinase 1; MAPK, mitogen-activated kinase; CDK, cyclin-dependent kinase; Rb, retinoblastoma; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline.
2   J. D. Weber and J. J. Baldassare, unpublished observations.
3   A. Gardner, J. D. Weber, and J. J. Baldassare, unpublished observations.

ACKNOWLEDGEMENTS

We thank Dr. Charles Sherr for murine cyclin D1 cDNA and Dr. Mark Ewen for GST-Rb cDNA.


REFERENCES

  1. Weber, J. D., Raben, D. M., Phillips, P. J., and Baldassare, J. J. (1997) Biochem J., in press
  2. Sherr, C. J. (1995) Trends Biochem. Sci. 20, 187-190 [CrossRef][Medline] [Order article via Infotrieve]
  3. Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J.-Y., Bar-Sagi, D., Roussel, M. F., and Sherr, C. J. (1993) Genes Dev. 7, 1559-1571 [Abstract]
  4. Baldin, V., Lukas, J., Marcote, M. J., Pagano, M., and Draetta, G. (1993) Genes Dev. 7, 812-821 [Abstract]
  5. Matsushime, H., Roussel, M. F., Ashmun, R. A., and Sherr, C. J. (1991) Cell 65, 701-713 [Medline] [Order article via Infotrieve]
  6. Lavoie, J. N., L'Allemain, G., Brunet, A., Muller, R., and Pouyssegur, J. (1996) J. Biol. Chem. 271, 20608-20616 [Abstract/Free Full Text]
  7. Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., and Sherr, C. J. (1992) Cell 71, 323-334 [Medline] [Order article via Infotrieve]
  8. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and Kato, J.-Y. (1994) Mol. Cell. Biol. 14, 2066-2076 [Abstract]
  9. Sherr, C. J. (1994) Cell 79, 551-555 [Medline] [Order article via Infotrieve]
  10. Bates, S., Bonetta, L., MacAllan, D., Parry, D., Holder, A., Dickson, C., and Peters, G. (1994) Oncogene 9, 71-79 [Medline] [Order article via Infotrieve]
  11. Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J., and Livingston, D. M. (1993) Cell 73, 487-497 [Medline] [Order article via Infotrieve]
  12. Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., and Weinberg, R. A. (1993) Cell 73, 499-511 [Medline] [Order article via Infotrieve]
  13. Kato, J.-Y., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. (1993) Genes Dev. 7, 331-342 [Abstract]
  14. Resnitzky, D., Gossen, M., Bujard, H., and Reed, S. I. (1994) Mol. Cell. Biol. 14, 1669-1679 [Abstract]
  15. Sherr, C. J., and Roberts, J. M. (1995) Genes Dev. 9, 1149-1163 [CrossRef][Medline] [Order article via Infotrieve]
  16. Grana, X., and Reddy, E. P. (1995) Oncogene 11, 211-219 [Medline] [Order article via Infotrieve]
  17. Filmus, J., Robles, A. I., Shi, W., Wong, M. J., Colombo, L. L., and Conti, C. J. (1994) Oncogene 9, 3627-3633 [Medline] [Order article via Infotrieve]
  18. Liu, J., Chao, J., Jiang, M., Yung, S., Yen, J. J., and Yang-Yen, H. (1995) Mol. Cell. Biol. 15, 3654-3663 [Abstract]
  19. Winston, J. T., Coats, S. R., Wang, Y.-Z., and Pledger, W. J. (1996) Oncogene 12, 127-134 [Medline] [Order article via Infotrieve]
  20. van Biesen, T., Hawes, B. E., Raymond, J. R., Luttrell, L. M., Koch, W. J., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 1266-1269 [Abstract/Free Full Text]
  21. Faure, M., Voyno-Yasenetskaya, T. A., and Bourne, H. R. (1994) J. Biol. Chem. 269, 7851-7854 [Abstract/Free Full Text]
  22. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420 [CrossRef][Medline] [Order article via Infotrieve]
  23. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12706-12710 [Abstract/Free Full Text]
  24. Vouret-Craviari, V., Van Obberghen-Schilling, E., Scimeca, J. C., Van Obberghen, E., and Pouyssegur, J. (1993) Biochem. J. 289, 209-214 [Medline] [Order article via Infotrieve]
  25. Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., and Pestell, R. G. (1995) J. Biol. Chem. 270, 23589-23597 [Abstract/Free Full Text]
  26. Li, Y. C., and Lieberman, M. W. (1989) Oncogene 4, 795-798 [Medline] [Order article via Infotrieve]
  27. Hinds, P. W., Dowdy, S. F., Eaton, E. N., Arnold, A., and Weinberg, R. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 709-713 [Abstract]
  28. Lovec, H., Sewing, A., Lucibello, F. C., Muller, R., and Moroy, T. (1994) Oncogene 9, 323-326 [Medline] [Order article via Infotrieve]
  29. Inglese, J., Koch, W. J., Touhara, K., and Lefkowitz, R. J. (1995) Trends Biochem. Sci. 20, 151-156 [CrossRef][Medline] [Order article via Infotrieve]
  30. Murtagh, J. J., Eddy, R., Shows, T. B., Moss, J., and Vaughan, M. (1991) Mol. Cell. Biol. 11, 1146-1155 [Medline] [Order article via Infotrieve]
  31. Callen, D. F., Doggett, N. A., Stallings, R. L., Chen, L. Z., Whitmore, S. A., Lane, S. A., Nancarrow, J. K., Apostolou, S., Thompson, A. D., Lapsys, N. M., Eyre, H. J., Baker, E. G., Shen, Y., Holman, K., Phillips, H., Richards, R. I., and Sutherland, G. R. (1992) Genomics 13, 1178-1185 [Medline] [Order article via Infotrieve]
  32. Wilkie, T. M., Gilbert, D. J., Olsen, A. S., Chen, X., Amatruda, T. T., Korenberg, J. R., Trasj, B. J., de Jong, P., Reed, R. R., Simon, M. I., Jenkins, N. A., and Copeland, N. G. (1992) Nature Genet. 1, 85-91 [Medline] [Order article via Infotrieve]
  33. Doggett, N. A., Breuning, M. H., and Callen, D. F. (1996) Cytogenet. Cell Genet. 72, 271-293 [Medline] [Order article via Infotrieve]
  34. Douglass, E. C., Rowe, S. T., Valentine, M., Parham, D., Meyer, W. H., and Thompson, E. I. (1990) Cytogenet. Cell Genet. 53, 87-90 [Medline] [Order article via Infotrieve]
  35. Huff, V., Reeve, A. E., Leppert, M., Strong, L. C., Douglass, E. C., Geiser, C. F., Li, F. P., Meadows, A., Callen, D. F., Lenoir, G., and Saunders, G. F. (1992) Cancer Res. 52, 6117-6120 [Abstract]
  36. Bardi, G., Johansson, B., Pandis, N., Mandahl, N., Bak-Jensen, E., Lindstrom, C., Tornqvist, A., Frederiksen, H., Andren-Sandberg, A., Mitelman, F., and Heim, S. (1993) Int. J. Cancer 55, 422-428 [Medline] [Order article via Infotrieve]
  37. Veronese, M. L., Bullrich, F., Negrini, M., and Croce, C. M. (1996) Cancer Res. 56, 728-732 [Abstract]
  38. Anamthawat-Jonsson, K., Eyfjord, J. E., Ogmundsdottir, H. M., Petursdottir, I., and Steinarsdottir, M. (1996) Cancer Genet. Cytogen. 88, 1-7 [Medline] [Order article via Infotrieve]
  39. Mandahl, N., Mertens, F., Willen, H., Rydholm, A., Brosjo, O., and Mitelman, F. (1994) J. Cancer Res. Clin. Oncol. 120, 707-711 [Medline] [Order article via Infotrieve]
  40. Biggs, P. J., Wooster, R., Ford, D., Chapman, P., Mangion, J., Quirk, Y., Easton, D. F., Burn, J., and Stratton, M. R. (1995) Nature Genet. 11, 441-443 [Medline] [Order article via Infotrieve]
  41. Newsham, I., Kindler-Rohrborn, A., Daub, D., and Cavenee, W. (1995) Genes Chromosomes & Cancer 12, 1-7 [Medline] [Order article via Infotrieve]
  42. Tsuda, H., and Hirohashi, S. (1995) Cancer Res. 55, 3395-3398 [Abstract]
  43. Dorion-Bonnet, F., Mautalen, S., Hostein, I., and Longy, M. (1995) Genes Chromosomes & Cancer 14, 171-181 [Medline] [Order article via Infotrieve]
  44. Panagopoulos, I., Mandahl, N., Mitelman, F., and Aman, P. (1995) Oncogene 11, 1133-1137 [Medline] [Order article via Infotrieve]
  45. McManus, A. P., Min, T., Swansbury, G. J., Gusterson, B. A., Pinkerton, C. R., and Shipley, J. M. (1996) Cancer Genet. Cytogen. 87, 179-181 [CrossRef][Medline] [Order article via Infotrieve]
  46. Low, D. A., Scott, R. W., Baker, J. B., and Cunningham, D. D. (1982) Nature 298, 476-478 [Medline] [Order article via Infotrieve]
  47. Downward, J., Graves, J. D., Warne, P. H., Rayter, S., and Cantrell, D. A. (1990) Nature 346, 719-723 [CrossRef][Medline] [Order article via Infotrieve]
  48. Cheng, J., Weber, J. D., Baldassare, J. J., and Raben, D. M. (1997) J. Biol. Chem. 272, 17312-17319 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.